Israeli company Medial EarlySign has launched an AI-based product called ColonFlag to analyse electronic health records to identify patients with early-stage colorectal cancer or those at high risk of developing the disease. The aim is to increase screening tests for at-risk individuals. The Israeli company has also launched products to identify Diabetes Type 2 patients at risk of developing chronic kidney disease. The tools will be showcased at a meeting of the American Diabetes Association in next week.
Israeli company Medial EarlySign has launched an AI-based product called ColonFlag to analyse electronic health records to identify patients with early-stage colorectal cancer or those at high risk of developing the disease. The aim is to increase screening tests for at-risk individuals. The Israeli company has also launched products to identify Diabetes Type 2 patients at risk of developing chronic kidney disease. The tools will be showcased at a meeting of the American Diabetes Association in June.